Author

Nasreen C. Marikar

University of Colorado Boulder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Research Focus:cell type annotation· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:imaging· 1 Assay:proteomics· 1

Frequent Co-Authors

Sabrina L. SpenceriD· 3 shared Varuna NangiaiD· 2 shared Agnieszka Katarzyna WitkiewicziD· 1 shared Alicia M. DarnelliD· 1 shared Brianna Fernandez· 1 shared Chance C. SineiD· 1 shared Christopher Ryland IlliD· 1 shared Erik S. KnudseniD· 1 shared

Activity by Year

2024-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 23 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Sabrina L. SpencerORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

p16 expression confers sensitivity to CDK2 inhibitors

Chance C. Sine, Lotte P. Watts, Brianna Fernandez, Nasreen C. Marikar, Jianxin Wang, Erik S. Knudsen, Agnieszka Katarzyna Witkiewicz, Sabrina L. Spencer

The paper shows that p16 expression in ovarian cancers increases sensitivity to CDK2 inhibitors by inhibiting CDK4/6, suggesting p16 as a biomarker for CDK2 inhibitor response.

Science Signaling · Nov 25, 2025Peer-reviewedCancer Biology

MAPK and mTORC1 signaling converge on Cyclin D to enable cell-cycle re-entry in melanoma persister cells

Varuna Nangia, Humza M. Ashraf, Nasreen C. Marikar, Victor J. Passanisi, R. Christopher, Sabrina L. Spencer

The paper identifies Cyclin D1 accumulation as a critical bottleneck for cell-cycle re-entry in drug-treated melanoma cells, driven by MAPK and mTORC1 signaling integration.

Science Signaling · Sep 2, 2025Peer-reviewedSystems Biology

BRAF V600 and ErbB inhibitors directly activate GCN2 in an off-target manner to limit cancer cell proliferation

Christopher Ryland Ill, Nasreen C. Marikar, Vu Nguyen, Varuna Nangia, Alicia M. Darnell, Matthew G. Vander Heiden, Philip Reigan, Sabrina L. Spencer

The paper identifies off-target activation of GCN2 by BRAF and EGFR inhibitors, showing it limits cancer cell proliferation.

bioRxiv · Dec 19, 2024 · PreprintCancer Biology